Mario Paolo Colombo

List of Publications by Year
in descending order

296 papers	24,430 citations	8749 75 h-index	8384 147 g-index
313 all docs	313 docs citations	313 times ranked	27903 citing authors

#	Article	IF	Citations
1	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	7.7	124
2	Few, but Efficient: The Role of Mast Cells in Breast Cancer and Other Solid Tumors. Cancer Research, 2022, 82, 1439-1447.	0.4	18
3	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15â€“16, 2020. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	0
4	Release of IFNÎ³ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. Clinical Cancer Research, 2022, 28, 3141-3155.	3.2	20
5	Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation. ELife, 2022, 11, .	2.8	5
6	CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy. Blood Advances, 2022, 6, 4471-4484.	2.5	5
7	SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model. Oncogene, 2022, 41, 4055-4065.	2.6	10
8	Immune-tolerance to human iPS-derived neural progenitors xenografted into the immature cerebellum is overridden by species-specific differences in differentiation timing. Scientific Reports, 2021, 11, 651.	1.6	6
9	Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. Frontiers in Immunology, 2021, 12, 622001.	2.2	6
10	The evolutionarily conserved long nonâ€coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. Molecular Oncology, 2021, 15, 1921-1941.	2.1	22
11	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. Cellular Immunology, 2021, 362, 104301.	1.4	12
12	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 2429-2438.	2.0	10
13	CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. Frontiers in Immunology, 2021, 12, 662048.	2.2	3
14	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. Cancer Immunology Research, 2021, 9, 825-837.	1.6	6
15	Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. Cancer Research, 2021, 81, 4257-4274.	0.4	11
16	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. IScience, 2021, 24, 102510.	1.9	5
17	Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended. Cancers, 2021, 13, 4028.	1.7	6
18	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. Cancers, 2021, 13, 4081.	1.7	5

#	Article	IF	Citations
19	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313.	3.2	8
20	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11â€“13 2019, Verona, Italy. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	0
21	A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. IScience, 2020, 23, 101562.	1.9	27
22	Immunometabolic Status of COVID-19 Cancer Patients. Physiological Reviews, 2020, 100, 1839-1850.	13.1	20
23	Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. EBioMedicine, 2020, 61, 103055.	2.7	21
24	T Cell Costimulation Blockade Blunts Age-Related Heart Failure. Circulation Research, 2020, 127, 1115-1117.	2.0	19
25	Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCSâ€“Istituto Nazionale dei Tumori di Milano. Tumori, 2020, 106, 193-202.	0.6	32
26	Infiltrating Mast Cellâ€“Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype. Cancer Research, 2020, 80, 2311-2324.	0.4	28
27	Tumor-Derived Prostaglandin E2 Promotes p50 NF-ÎºB-Dependent Differentiation of Monocytic MDSCs. Cancer Research, 2020, 80, 2874-2888.	0.4	81
28	Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models.. Journal of Clinical Oncology, 2020, 38, 9547-9547.	0.8	2
29	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS ONE, 2019, 14, e0220644.	1.1	6
30	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology (Dordrecht), 2019, 42, 815-828.	2.1	11
31	SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. Frontiers in Immunology, 2019, 10, 1369.	2.2	44
32	Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations. Annals of Oncology, 2019, 30, v800.	0.6	0
33	Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overloadâ€“Driven Heart Failure Reveals Extent of Immune Activation. Circulation, 2019, 140, 2089-2107.	1.6	212
34	The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene, 2019, 38, 3636-3650.	2.6	144
35	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. Cancers, 2019, 11, 624.	1.7	32
36	ILâ€10â€producing BÂcells are characterized by a specific methylation signature. European Journal of Immunology, 2019, 49, 1213-1225.	1.6	19

#	Article	IF	Citations
37	DNA threads released by activated CD4 ⁺ T lymphocytes provide autocrine costimulation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8985-8994.	3.3	33
38	When Failure Is Worse Than Giving Up: The Case of CTL. Cancer Research, 2019, 79, 1753-1755.	0.4	0
39	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer, 2019, 132, 72-78.	0.9	54
40	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open, 2019, 4, e000457.	2.0	151
41	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treatment Reviews, 2019, 75, 39-51.	3.4	124
42	Frontline Science: Mast cells regulate neutrophil homeostasis by influencing macrophage clearance activity. Journal of Leukocyte Biology, 2019, 105, 633-644.	1.5	7
43	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 1938-1951.	0.4	58
44	Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. Cancer Research, 2019, 80, canres.1425.2019.	0.4	13
45	A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy. DMM Disease Models and Mechanisms, 2019, 13, .	1.2	16
46	OA14.06 Hyperprogressive Disease in Advanced Nonâ€"Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2019, 14, S245.	0.5	1
47	Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity?. Clinical Cancer Research, 2019, 25, 453-454.	3.2	6
48	Antibodyâ€"Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€"small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999.	3.2	315
49	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clinical Lung Cancer, 2019, 20, e413-e417.	1.1	27
50	Abstract SY35-02: Bone marrow remodeling in response to distant tumor starts early in transformation. , 2019, , .		0
51	Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia. Blood, 2019, 134, 2332-2332.	0.6	0
52	Interferon-Î³-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment. Blood, 2019, 134, 1212-1212.	0.6	2
53	Abstract SY35-02: Bone marrow remodeling in response to distant tumor starts early in transformation. , 2019, , .		0
54	Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. Cancer Immunology Research, 2018, 6, 552-565.	1.6	44

#	Article	IF	Citations
55	cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. Cell Death and Differentiation, 2018, 25, 2147-2164.	5.0	15
56	Mast cells, basophils and eosinophils: From allergy to cancer. Seminars in Immunology, 2018, 35, 29-34.	2.7	66
57	Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans. Inflammatory Bowel Diseases, 2018, 24, 136-148.	0.9	11
58	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. OncoImmunology, 2018, 7, e1465164.	2.1	3
59	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Research, 2018, 78, 5729-5730.	0.4	11
60	Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. BMC Cancer, 2018, 18, 899.	1.1	45
61	Role of PD-L1 expression in triple-negative breast cancer stem cells.. Journal of Clinical Oncology, 2018, 36, 12081-12081.	0.8	1
62	Abstract A24: Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, epithelial malignancy. , 2018, , .		0
63	Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation. , 2018, , .		0
64	Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling. Blood, 2018, 132, 2579-2579.	0.6	0
65	Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. Journal of Leukocyte Biology, 2017, 102, 287-292.	1.5	20
66	Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. Cancer Immunology, Immunotherapy, 2017, 66, 1059-1067.	2.0	36
67	Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen. Cancer Research, 2017, 77, 3644-3654.	0.4	55
68	Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. Trends in Immunology, 2017, 38, 648-656.	2.9	66
69	Reciprocal influence of B cells and tumor macro and microenvironments in theApc^{Min/+}model of colorectal cancer. OncoImmunology, 2017, 6, e1336593.	2.1	8
70	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. Cancer Research, 2017, 77, 3685-3699.	0.4	27
71	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 5149-5161.	3.2	59
72	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelialâ€“Stromal Tumors by Targeting PDGFR-Î². Molecular Cancer Therapeutics, 2017, 16, 365-375.	1.9	11

#	Article	IF	Citations
73	On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?. Clinical Cancer Research, 2017, 23, 5999-6001.	3.2	10
74	The good and bad of targeting cancer-associated extracellular matrix. Current Opinion in Pharmacology, 2017, 35, 75-82.	1.7	23
75	Antibodyâ€mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB Journal, 2017, 31, 5356-5370.	0.2	10
76	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). Cytokine and Growth Factor Reviews, 2017, 36, 1-3.	3.2	1
77	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. Frontiers in Immunology, 2017, 8, 1918.	2.2	72
78	Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial. Annals of Oncology, 2017, 28, v50.	0.6	0
79	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. Cell Reports, 2016, 17, 233-248.	2.9	84
80	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications, 2016, 7, 12150.	5.8	2,076
81	Healthy and tumoral tissue resistivity in wild-type and sparcâ€"/â€" animal models. Medical and Biological Engineering and Computing, 2016, 54, 1949-1957.	1.6	7
82	CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-ÎºB signaling. Oncogene, 2016, 35, 3944-3954.	2.6	51
83	TNF-Related Apoptosis-Inducing Ligand (TRAIL)â€"Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. Clinical Cancer Research, 2016, 22, 3499-3512.	3.2	158
84	CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget, 2016, 7, 79925-79942.	0.8	40
85	Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget, 2016, 7, 3905-3920.	0.8	9
86	Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. , 2016, , .		0
87	Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells. Blood, 2016, 128, 3711-3711.	0.6	0
88	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
89	Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. Cancer Research, 2015, 75, 3760-3770.	0.4	27
90	Regulated Expression of miR-155 is Required for iNKT Cell Development. Frontiers in Immunology, 2015, 6, 140.	2.2	22

#	Article	IF	Citations
91	The ins and outs of osteopontin. OncoImmunology, 2015, 4, e978711.	2.1	3
92	SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. Cancer Research, 2015, 75, 2387-2399.	0.4	39
93	CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin. Clinical Cancer Research, 2015, 21, 146-156.	3.2	42
94	SCD5â€induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. Journal of Pathology, 2015, 236, 315-325.	2.1	34
95	RORC1 Regulates Tumor-Promoting â€œEmergencyâ€•Granulo-Monocytopoiesis. Cancer Cell, 2015, 28, 253-269.	7.7	154
96	The Role of Mast Cells in Molding the Tumor Microenvironment. Cancer Microenvironment, 2015, 8, 167-176.	3.1	62
97	Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment. Cancer Immunology Research, 2015, 3, 85-95.	1.6	59
98	OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.. Journal of Clinical Oncology, 2015, 33, e16576-e16576.	0.8	0
99	Abstract 4054: Mast cells contribute to T cell tolerance against prostate cancer- associated antigens favoring tumor growth. , 2015, , .		0
100	MEF2C and SOCS2 in stemness regulation. Oncoscience, 2015, 2, 936-937.	0.9	2
101	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. Blood, 2015, 126, 1019-1019.	0.6	0
102	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
103	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. OncoImmunology, 2014, 3, e28989.	2.1	34
104	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. Cancer Discovery, 2014, 4, 110-129.	7.7	100
105	Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity. Neoplasia, 2014, 16, 1047-1058.	2.3	78
106	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	3.1	37
107	Editors' Viewpointâ€"Response. Cancer Research, 2014, 74, 635-635.	0.4	0
108	Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. Growth Factors, 2014, 32, 41-52.	0.5	18

#	Article	IF	Citations
109	Osteopontin Shapes Immunosuppression in the Metastatic Niche. Cancer Research, 2014, 74, 4706-4719.	0.4	110
110	Mast Cells Control the Expansion and Differentiation of IL-10â€"Competent B Cells. Journal of Immunology, 2014, 193, 4568-4579.	0.4	33
111	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood, 2014, 123, 1836-1849.	0.6	37
112	Mast Cells and Immune Response in Cancer. , 2014, , 77-98.		0
113	The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miRâ€221&222â€câ€FOS pathway. International Journal of Cancer, 2013, 133, 879-892.	2.3	55
114	IL-15 cis Presentation Is Required for Optimal NK Cell Activation in Lipopolysaccharide-Mediated Inflammatory Conditions. Cell Reports, 2013, 4, 1235-1249.	2.9	66
115	Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1811-1819.	2.0	3
116	Antiâ€tumor activity of CpGâ€ODN aerosol in mouse lung metastases. International Journal of Cancer, 2013, 133, 383-393.	2.3	20
117	Inhibiting Interactions of Lysine Demethylase LSD1 with Snail/Slug Blocks Cancer Cell Invasion. Cancer Research, 2013, 73, 235-245.	0.4	117
118	Convergences and Divergences of Thymus- and Peripherally Derived Regulatory T Cells in Cancer. Frontiers in Immunology, 2013, 4, 247.	2.2	25
119	Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. Cell Death and Disease, 2013, 4, e920-e920.	2.7	41
120	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. PLoS ONE, 2013, 8, e56761.	1.1	41
121	Abstract A102: Osteopontin produced by myeloid cells determines the outcome of breast cancer metastases. , 2013, , .		3
122	Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients. Antiviral Therapy, 2012, 17, 111-118.	0.6	12
123	Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. International Journal of Molecular Sciences, 2012, 13, 15107-15125.	1.8	33
124	The Dark Side of Mast Cellâ€"Targeted Therapy in Prostate Cancer. Cancer Research, 2012, 72, 831-835.	0.4	52
125	The Aryl Hydrocarbon Receptor Modulates Acute and Late Mast Cell Responses. Journal of Immunology, 2012, 189, 120-127.	0.4	70
126	Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas. Advances in Hematology, 2012, 2012, 1-12.	0.6	15

#	Article	IF	Citations
127	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood, 2012, 120, 3541-3554.	0.6	44
128	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood, 2012, 120, 3007-3018.	0.6	350
129	Modulation of FcÎµRI-dependent mast cell response by OX40L via Fyn, PI3K, and RhoA. Journal of Allergy and Clinical Immunology, 2012, 130, 751-760.e2.	1.5	23
130	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. American Journal of Pathology, 2011, 179, 3000-3010.	1.9	62
131	The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. Journal of Autoimmunity, 2011, 37, 300-310.	3.0	29
132	Constitutive activation of the ETSâ€1â€miRâ€222 circuitry in metastatic melanoma. Pigment Cell and Melanoma Research, 2011, 24, 953-965.	1.5	36
133	Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene, 2011, 30, 757-769.	2.6	70
134	Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient KitW-sh/W-sh mice. Laboratory Investigation, 2011, 91, 627-641.	1.7	61
135	Intratumor OX40 stimulation inhibits IRF1 expression and ILâ€10 production by Treg cells while enhancing CD40L expression by effector memory T cells. European Journal of Immunology, 2011, 41, 3615-3626.	1.6	39
136	The bone marrow stroma in hematological neoplasmsâ€"a guilty bystander. Nature Reviews Clinical Oncology, 2011, 8, 456-466.	12.5	42
137	Mast Cell Targeting Hampers Prostate Adenocarcinoma Development but Promotes the Occurrence of Highly Malignant Neuroendocrine Cancers. Cancer Research, 2011, 71, 5987-5997.	0.4	124
138	Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer and Metastasis Reviews, 2010, 29, 295-307.	2.7	207
139	Peripheral regulatory T cells and serum transforming growth factor-Î²: Relationship with clinical response to infliximab in CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2010, 16, 1891-1897.	0.9	40
140	A nonâ€redundant role for OX40 in the competitive fitness of Treg in response to ILâ€2. European Journal of Immunology, 2010, 40, 2902-2913.	1.6	62
141	Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis. Cancer Research, 2010, 70, 7764-7775.	0.4	31
142	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. Cancer Research, 2010, 70, 9062-9072.	0.4	126
143	Xg Expression in Ewing's Sarcoma Is of Prognostic Value and Contributes to Tumor Invasiveness. Cancer Research, 2010, 70, 3730-3738.	0.4	21
144	Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. Journal of Experimental Medicine, 2010, 207, 2931-2942.	4.2	175

#	Article	IF	Citations
145	Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma. American Journal of Pathology, 2010, 177, 792-802.	1.9	82
146	CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. Journal of Clinical Investigation, 2010, 120, 668-680.	3.9	150
147	Polyps Wrap Mast Cells and Treg within Tumorigenic Tentacles. Cancer Research, 2009, 69, 5619-5622.	0.4	17
148	An unusual BRCA2 allele carrying two splice site mutations. Annals of Oncology, 2009, 20, 1143-1144.	0.6	8
149	Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood, 2009, 114, 2639-2648.	0.6	184
150	CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction. Immunity, 2008, 29, 771-781.	6.6	333
151	Matricellular proteins at the crossroad of inflammation and cancer. Cancer Letters, 2008, 267, 245-253.	3.2	33
152	The Promyelocytic Leukemia Zinc Fingerâ€"MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms. Cancer Research, 2008, 68, 2745-2754.	0.4	357
153	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of antiâ€"Salmonella typhimurium immunity. Journal of Experimental Medicine, 2008, 205, 657-667.	4.2	22
154	OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. Journal of Experimental Medicine, 2008, 205, 1505-1505.	4.2	2
155	Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. Cancer Research, 2008, 68, 9050-9059.	0.4	174
156	OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. Journal of Experimental Medicine, 2008, 205, 825-839.	4.2	369
157	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of antiâ€"Salmonella typhimuriumimmunity. Journal of Cell Biology, 2008, 180, i17-i17.	2.3	0
158	The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Research, 2007, 67, 425-425.	0.4	649
159	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Annals of Oncology, 2007, 18, 226-232.	0.6	252
160	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.4	81
161	Amino-Biphosphonateâ€"Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma. Cancer Research, 2007, 67, 11438-11446.	0.4	310
162	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25â˜' into CD25+ T regulatory cells. Blood, 2007, 109, 2871-2877.	0.6	357

#	Article	IF	Citations
163	Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nature Reviews Cancer, 2007, 7, 880-887.	12.8	379
164	Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells, 2006, 24, 454-461.	1.4	123
165	Triggering CD40 on endothelial cells contributes to tumor growth. Journal of Experimental Medicine, 2006, 203, 2441-2450.	4.2	73
166	CD99 Acts as an Oncosuppressor in Osteosarcoma. Molecular Biology of the Cell, 2006, 17, 1910-1921.	0.9	60
167	CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine. Journal of Immunology, 2006, 176, 1750-1758.	0.4	96
168	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. Cancer Research, 2006, 66, 2442-2450.	0.4	129
169	Tumor-Induced Expansion of Regulatory T Cells by Conversion of CD4+CD25â˜ Lymphocytes Is Thymus and Proliferation Independent. Cancer Research, 2006, 66, 4488-4495.	0.4	230
170	p50 Nuclear Factor-ÎºB Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor Resistance. Cancer Research, 2006, 66, 11432-11440.	0.4	397
171	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. Journal of Clinical Investigation, 2006, 116, 2777-2790.	3.9	723
172	Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood, 2005, 105, 2845-2851.	0.6	358
173	Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood, 2005, 106, 3846-3853.	0.6	110
174	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene, 2005, 24, 4349-4361.	2.6	90
175	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Experimental Hematology, 2005, 33, 1521-1530.	0.2	44
176	CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. European Journal of Immunology, 2005, 35, 557-567.	1.6	108
177	Chaperon and Adjuvant Activity of hsp70: Different Natural Killer Requirement for Cross-Priming of Chaperoned and Bystander Antigens. Cancer Research, 2005, 65, 7942-7949.	0.4	43
178	Targeting Myelomonocytic Cells to Revert Inflammation-Dependent Cancer Promotion: Figure 1.. Cancer Research, 2005, 65, 9113-9116.	0.4	88
179	RedirectingIn vivoElicited Tumor Infiltrating Macrophages and Dendritic Cells towards Tumor Rejection. Cancer Research, 2005, 65, 3437-3446.	0.4	498
180	Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. Journal of Cell Science, 2005, 118, 3685-3694.	1.2	60

#	Article	IF	Citations
181	Reconstitution of Human Telomerase Reverse Transcriptase Expression Rescues Colorectal Carcinoma Cells from In vitro Senescence: Evidence against Immortality as a Constitutive Trait of Tumor Cells. Cancer Research, 2005, 65, 2321-2329.	0.4	26
182	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4185-4190.	3.3	271
183	Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. Cancer Research, 2005, 65, 3920-3927.	0.4	157
184	IL-21 Induces Tumor Rejection by Specific CTL and IFN-Î³-Dependent CXC Chemokines in Syngeneic Mice. Journal of Immunology, 2004, 172, 1540-1547.	0.4	146
185	Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor. Journal of Immunology, 2004, 172, 4026-4036.	0.4	38
186	Role of PLZF in melanoma progression. Oncogene, 2004, 23, 4567-4576.	2.6	62
187	Molecular mechanisms of CD99-induced caspase-independent cell death and cellâ€"cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene, 2004, 23, 5664-5674.	2.6	108
188	Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis. Cancer Immunology, Immunotherapy, 2004, 53, 600-608.	2.0	22
189	CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2?specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunology, Immunotherapy, 2004, 53, 697-704.	2.0	6
190	Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70. Cancer Research, 2004, 64, 1502-1508.	0.4	60
191	HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1626, 1-9.	2.4	18
192	Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma. Journal of Experimental Medicine, 2003, 198, 1475-1485.	4.2	124
193	OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response. Journal of Immunology, 2003, 170, 99-106.	0.4	67
194	Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo. Journal of Experimental Medicine, 2003, 198, 1253-1263.	4.2	107
195	IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. Journal of Immunology, 2003, 170, 270-278.	0.4	445
196	Autologous and MHC class Iâ€"negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood, 2003, 101, 568-575.	0.6	24
197	Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood, 2003, 102, 2138-2145.	0.6	260
198	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation, 2003, 111, 1161-1170.	3.9	27

#	Article	IF	Citations
199	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation, 2003, 111, 1161-1170.	3.9	105
200	Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice. Journal of Immunology, 2002, 169, 151-158.	0.4	34
201	Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Antiâ€"Interleukin 10 Receptor Antibody. Journal of Experimental Medicine, 2002, 196, 541-549.	4.2	322
202	Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine and Growth Factor Reviews, 2002, 13, 155-168.	3.2	627
203	Introduction: Cytokines and Cancer. Cytokine and Growth Factor Reviews, 2002, 13, 93-94.	3.2	4
204	Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. Cancer Genetics and Cytogenetics, 2002, 139, 126-132.	1.0	7
205	IFN-Î³-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. European Journal of Immunology, 2002, 32, 1914.	1.6	42
206	Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunology, Immunotherapy, 2002, 51, 9-14.	2.0	38
207	Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Cancer Research, 2002, 62, 4390-7.	0.4	25
208	The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 2001, 97, 339-345.	0.6	375
209	Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunology, Immunotherapy, 2001, 50, 199-211.	2.0	16
210	Different requirements for Î±-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. European Journal of Immunology, 2001, 31, 3101-3110.	1.6	19
211	IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk. Journal of Immunology, 2001, 166, 3890-3899.	0.4	157
212	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. Journal of Experimental Medicine, 2001, 194, 1195-1206.	4.2	218
213	Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. Journal of Neurosurgery, 2000, 92, 419-427.	0.9	60
214	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. Journal of Cellular Physiology, 2000, 185, 317-323.	2.0	26
215	Modulation of host immune responses stimulated bySalmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen. European Journal of Immunology, 2000, 30, 768-777.	1.6	28
216	Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood, 2000, 96, 1125-1129.	0.6	140

#	Article	IF	Citations
217	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. Journal of Immunology, 2000, 165, 5133-5142.	0.4	326
218	Immunizing Potential of Cytokine-Transduced Tumor Cells. , 2000, 35, 3-26.		0
219	Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood, 2000, 96, 1125-1129.	0.6	2
220	The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8489-8492.	3.3	198
221	Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells. Human Gene Therapy, 1999, 10, 2907-2916.	1.4	61
222	Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response. Journal of Experimental Medicine, 1999, 190, 125-134.	4.2	168
223	DNA vaccination against the ovarian carcinoma-associated antigen folate receptor Î± (FRÎ±) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Therapy, 1999, 6, 349-357.	2.2	17
224	Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. Gene Therapy, 1999, 6, 865-872.	2.3	21
225	Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. Oncogene, 1999, 18, 1993-2001.	2.6	54
226	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. Cancer Immunology, Immunotherapy, 1999, 48, 132-138.	2.0	8
227	Salmonella vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. European Journal of Immunology, 1999, 29, 693-699.	1.6	56
228	Interleukin-12 as an Adjuvant for Cancer Immunotherapy. Methods, 1999, 19, 114-120.	1.9	60
229	Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. , 1998, 186, 390-397.		13
230	Tumor and dendritic cells as cellular vaccines: confrontation and perspectives â€“ a symposium in writing. Cancer Immunology, Immunotherapy, 1998, 46, 69-69.	2.0	2
231	HIV/gp120 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas-L upregulation. FEBS Letters, 1998, 436, 461-465.	1.3	11
232	Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. Oncogene, 1998, 16, 3285-3289.	2.6	78
233	Interferon Î³â€“independent Rejection of Interleukin 12â€“transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colonyâ€“stimulating Factor. Journal of Experimental Medicine, 1998, 188, 133-143.	4.2	54
234	Interleukin 12â€“mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. Journal of Experimental Medicine, 1998, 188, 589-596.	4.2	291

#	Article	IF	Citations
235	Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With Salmonellatyphimurium, Results in Protective Immunity Against a Murine Fibrosarcoma. Blood, 1998, 92, 3172-3176.	0.6	173
236	Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With Salmonellatyphimurium, Results in Protective Immunity Against a Murine Fibrosarcoma. Blood, 1998, 92, 3172-3176.	0.6	32
237	Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12. Journal of the National Cancer Institute, 1997, 89, 1049-1058.	3.0	158
238	Cytokine Gene Transduction in the Immunotherapy of Cancer. Advances in Pharmacology, 1997, 40, 259-307.	1.2	43
239	Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 Gene. Human Gene Therapy, 1997, 8, 1345-1353.	1.4	69
240	Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. FEBS Letters, 1997, 411, 87-92.	1.3	13
241	Differential Susceptibility to HIV-GP120â€"Sensitized Apoptosis in CD4+ T-Cell Clones With Different T-Helper Phenotypes: Role of CD95/CD95L Interactions. Blood, 1997, 89, 558-569.	0.6	51
242	Immunotherapy. I: Cytokine gene transfer strategies. , 1997, 16, 421-432.		22
243	Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunology, Immunotherapy, 1997, 44, 197-203.	2.0	67
244	Cytokines, tumour-cell death and immunogenicity: a question of choice. Trends in Immunology, 1997, 18, 32-36.	7.5	161
245	The defined attenuatedListeria monocytogenes Î"mpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. European Journal of Immunology, 1997, 27, 1570-1575.	1.6	49
246	Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. European Journal of Immunology, 1997, 27, 2375-2382.	1.6	47
247	B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. , 1996, 67, 769-776.		33
248	ILâ€1Î± geneâ€transfected human melanoma cells increase tumorâ€cell adhesion to endothelial cells and their retention in the lung of nude mice. International Journal of Cancer, 1996, 67, 856-863.	2.3	34
249	Immunotherapy I: Cyclosine gene transfer strategies. Cancer and Metastasis Reviews, 1996, 15, 317-328.	2.7	24
250	Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.. Journal of Experimental Medicine, 1996, 183, 317-322.	4.2	516
251	Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells. Human Gene Therapy, 1996, 7, 1955-1963.	1.4	83
252	CD4 T cells inhibitin vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. European Journal of Immunology, 1995, 25, 137-146.	1.6	120

#	Article	IF	Citations
253	A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. European Journal of Immunology, 1995, 25, 2737-2742.	1.6	48
254	Anin vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. International Journal of Cancer, 1995, 62, 572-578.	2.3	29
255	Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials?. Cancer Immunology, Immunotherapy, 1995, 41, 265-270.	2.0	20
256	Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. British Journal of Cancer, 1995, 72, 1224-1229.	2.9	42
257	IL-12 Inhibits Apoptosis Induced in a Human Th1 Clone by gp120/CD4 Cross-Linking and CD3/TCR Activation or by IL-2 Deprivation. Cellular Immunology, 1995, 161, 14-21.	1.4	59
258	A Human Melanoma Cell Line Transduced with an Interleukin-4 Gene by a Retroviral Vector Releases Biologically Active IL-4 and Maintains the Original Tumor Antigenic Phenotype. Human Gene Therapy, 1995, 6, 1427-1436.	1.4	13
259	Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?. Cancer Immunology, Immunotherapy, 1995, 41, 265-270.	2.0	2
260	Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes. Human Gene Therapy, 1994, 5, 1139-1150.	1.4	44
261	Refined localization of H7 and Ctt1 on distal mouse chromosome 9. Immunogenetics, 1994, 40, 79-81.	1.2	5
262	Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. International Journal of Cancer, 1994, 56, 853-857.	2.3	222
263	Expression of a growth arrest specific gene (gas-6) during liver regeneration: Molecular mechanisms and signalling pathways. Journal of Cellular Physiology, 1994, 158, 263-269.	2.0	7
264	Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?. Trends in Immunology, 1994, 15, 48-51.	7.5	255
265	In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. International Journal of Cancer, 1993, 54, 8-15.	2.3	68
266	Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1). Immunogenetics, 1993, 38, 157-60.	1.2	6
267	Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA. FEBS Letters, 1993, 335, 114-118.	1.3	8
268	The Role of Cytokines in Antitumor Immune Response: From Detection to Gene Therapy. ImmunoMethods, 1993, 3, 34-42.	0.8	0
269	Sequence of human GAS3/PM22 full-length cDNA. Gene, 1993, 126, 289-290.	1.0	10
270	Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.. Journal of Experimental Medicine, 1993, 178, 151-161.	4.2	171

#	Article	IF	Citations
271	Cytokine-Induced Tumor Immunogenicity: From Exogenous Cytokines to Gene Therapy. Journal of Immunotherapy, 1993, 14, 253-257.	1.2	24
272	Isolation and mapping to 17p12 â€“ 13 of the human homologous of the murine growth arrest specific Gas-3 gene. Human Molecular Genetics, 1992, 1, 331-334.	1.4	11
273	Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Research, 1992, 2, 181-190.	0.6	84
274	Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. Human Pathology, 1992, 23, 1326-1331.	1.1	36
275	Localization of growth arrest-specific genes on mouse Chromosomes 1, 7, 8, 11, 13, and 16. Mammalian Genome, 1992, 2, 130-134.	1.0	36
276	Expression of a growth arrest specific gene (gas-1) in transformed cells. British Journal of Cancer, 1992, 66, 27-31.	2.9	4
277	Cytokine gene transfer in tumor cells as an approach to antitumor therapy. International Journal of Clinical and Laboratory Research, 1992, 21, 278-282.	1.0	4
278	Multiple molecular alterations in mouse lung tumors. Molecular Carcinogenesis, 1992, 5, 155-160.	1.3	59
279	Down-regulation of SPARC/Osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in kirsten-MSV transformed fibroblasts. European Journal of Cancer & Clinical Oncology, 1991, 27, 58-62.	0.9	11
280	Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.. Journal of Experimental Medicine, 1991, 173, 889-897.	4.2	304
281	Tumor-cell-targeted cytokine gene therapy. Trends in Immunology, 1991, 12, 249-250.	7.5	5
282	The high lysability by lak cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. International Journal of Cancer, 1991, 47, 746-754.	2.3	52
283	Modulation of multidrug resistance by verapamil ormdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers inmdr-resistant human carcinoma (LoVo) line. International Journal of Cancer, 1990, 46, 727-732.	2.3	55
284	Effect of adrenergic and Ca2+ antagonists on increased ornithine decarboxylase expression in regenerating rat liver. Biochemical Pharmacology, 1990, 40, 1605-1613.	2.0	11
285	A TaqI RFLP at the gas-2 locus. Nucleic Acids Research, 1989, 17, 7545-7545.	6.5	0
286	Ava I RFLP at the gas-1 locus on mouse chromosome 12. Nucleic Acids Research, 1989, 17, 5415-5415.	6.5	3
287	Strain polymorphism and tentative mapping of mouse ornithine decarboxylase. Nucleic Acids Research, 1988, 16, 9075-9075.	6.5	2
288	Inheritance of a mutant histocompatibility gene and a new mammary tumor virus genome in the B6.KH-84 mouse strain. Immunogenetics, 1987, 26, 99-104.	1.2	8

#	Article	IF	Citations
289	Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. Biochimica Et Biophysica Acta: Reviews on Cancer, 1987, 907, 163-174.	3.3	3
290	Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes. International Journal of Cancer, 1986, 38, 923-927.	2.3	2
291	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. Research in Clinic and Laboratory, 1986, 16, 1-20.	0.3	7
292	Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells. Cancer Immunology, Immunotherapy, 1985, 20, 198-204.	2.0	10
293	Genetic Unresponsiveness to a Murine Fibrosarcoma Determined by the Host Genetic Environment but not by Lymphocyte Precursor Genotype. Tumori, 1985, 71, 91-96.	0.6	0
294	Passive adoptive immunotherapy of low-immunogenic BALB/C lymphoma by syngeneic alloimmune T lymphocytes. International Journal of Cancer, 1984, 34, 807-813.	2.3	12
295	In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas. International Journal of Cancer, 1983, 31, 483-489.	2.3	22
296	Cross-reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h-2 and non-h-2 alloimmune balb/c mice. International Journal of Cancer, 1982, 29, 323-332.	2.3	26